Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for Invivyd in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.02) per share for the quarter, down from their prior forecast of $0.02. HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.16 EPS and FY2029 earnings at $0.27 EPS.
Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $11.30 million during the quarter, compared to analysts' expectations of $34.45 million.
Separately, D. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Invivyd in a research note on Friday, May 16th.
Get Our Latest Stock Report on Invivyd
Invivyd Trading Up 12.0%
NASDAQ IVVD traded up $0.10 during trading on Friday, hitting $0.95. 3,013,670 shares of the company's stock were exchanged, compared to its average volume of 4,514,604. The company has a market cap of $113.93 million, a PE ratio of -0.48 and a beta of 0.40. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $2.74. The stock's 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.74.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Nuveen LLC acquired a new position in shares of Invivyd in the first quarter valued at approximately $65,000. Invesco Ltd. increased its stake in shares of Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after buying an additional 71,485 shares during the period. XTX Topco Ltd acquired a new position in shares of Invivyd in the first quarter valued at approximately $66,000. Jane Street Group LLC increased its stake in shares of Invivyd by 290.5% in the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after buying an additional 87,358 shares during the period. Finally, Barclays PLC increased its stake in shares of Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after buying an additional 9,207 shares during the period. Institutional investors and hedge funds own 70.36% of the company's stock.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Recommended Stories
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
